Program
lumacaftor
Also written as “LUM/IVA”, “Lumacaftor” and “VX-809”.
Its studies are mostly in Cystic Fibrosis · Cognitive Dysfunction, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vertex Pharmaceuticals | 210 open or running | phase 4since Aug 15, 2016 | Mar 18, 2009 | none ahead |
| Qanatpharma | 11 open or running | phase 2since May 5, 2025 | May 5, 2025 | May 2027phase 2 · NCT07695090 |
| Qanatpharma Canada | 10 open or running | phase 1since Jul 21, 2023 | Jul 21, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 8 studies since Mar 18, 2009.
- Jul 8, 2013Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT01897233 · 62 enrolled · United States, Canada
- Jul 10, 20132 phase 1 studies in Cystic FibrosisVertex Pharmaceuticals · NCT01899105, NCT01910415
- Aug 26, 2013Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT01931839 · 1,164 enrolled · United States, Australia, Austria and more
- Mar 11, 2015Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT02390219 · 46 enrolled · United States
- Jul 23, 2015Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT02514473 · 206 enrolled · United States, Australia, Belgium and more
- Sep 1, 2015Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT02544451 · 246 enrolled · United States, Australia, Belgium and more
- Aug 15, 2016Phase 4 study in Cystic FibrosisVertex Pharmaceuticals · NCT02875366 · 70 enrolled · Australia, United Kingdom
- Feb 9, 2017Phase 2 study in Cystic FibrosisVertex Pharmaceuticals · NCT03061331 · 20 enrolled · Netherlands
- Apr 19, 2017Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT03125395 · 57 enrolled · United States, Canada
- Jul 18, 2018Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT03601637 · 61 enrolled · United States, Canada
- Aug 7, 2018Phase 2 study in Cystic FibrosisVertex Pharmaceuticals · NCT03625466 · 51 enrolled · Germany
- Jan 15, 2020Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT04235140 · 52 enrolled · United States, Canada
- Jul 21, 2023Qanatpharma Canada's first study: phase 1 study in Healthy VolunteerNew to Qanatpharma CanadaQanatpharma Canada · NCT05968612 · 39 enrolled · Canada
- May 5, 2025Qanatpharma's first study: phase 2 study in Cognitive DysfunctionNew to QanatpharmaQanatpharma · NCT07695090 · 60 planned · Canada
Ahead
- May 2027Primary completion: phase 2 study in Cognitive DysfunctionQanatpharma · NCT07695090
TargetBeta
“Cystic fibrosis transmembrane conductance regulator stabiliser”ChEMBL 37, by rule
Other programs on CFTR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivacaftorrule | Vertex Pharmaceuticals | phase 4 | 78 |
| tezacaftorrule | Vertex Pharmaceuticals | phase 3 | 39 |
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07695090Cognitive Dysfunction · Canada | 2 | Recruiting | Qanatpharma | May 2027 | 60 |
| NCT05968612Healthy Volunteer · Canada | 1 | Completed | Qanatpharma Canada | Dec 18, 2023 | 39 |
| NCT04235140Cystic Fibrosis · United States, Canada | 3 | Completed | Vertex Pharmaceuticals | Aug 22, 2023 | 52 |
| NCT03625466Cystic Fibrosis · Germany | 2 | Completed | Vertex Pharmaceuticals | Oct 9, 2020 | 51 |
| NCT03601637Cystic Fibrosis · United States, Canada | 3 | Completed | Vertex Pharmaceuticals | Oct 29, 2021 | 61 |
| NCT03125395Cystic Fibrosis · United States, Canada | 3 | Completed | Vertex Pharmaceuticals | Jul 17, 2019 | 57 |
| NCT03061331Cystic Fibrosis · Netherlands | 2 | Completed | Vertex Pharmaceuticals | Sep 6, 2017 | 20 |
| NCT02875366Cystic Fibrosis · Australia, United Kingdom | 4 | Completed | Vertex Pharmaceuticals | Sep 2017 | 70 |
| NCT02544451Cystic Fibrosis · United States, Australia, Belgium and more | 3 | Completed | Vertex Pharmaceuticals | Aug 2018 | 246 |
| NCT02514473Cystic Fibrosis · United States, Australia, Belgium and more | 3 | Completed | Vertex Pharmaceuticals | Sep 2016 | 206 |
| NCT02390219Cystic Fibrosis · United States | 3 | Completed | Vertex Pharmaceuticals | Oct 2016 | 46 |
| NCT01931839Cystic Fibrosis · United States, Australia, Austria and more | 3 | Completed | Vertex Pharmaceuticals | Apr 2016 | 1,164 |
| NCT01910415Cystic Fibrosis · Netherlands | 1 | Completed | Vertex Pharmaceuticals | Mar 2014 | 200 |
| NCT01899105Cystic Fibrosis · United States | 1 | Completed | Vertex Pharmaceuticals | Aug 2013 | 28 |
| NCT01897233Cystic Fibrosis · United States, Canada | 3 | Completed | Vertex Pharmaceuticals | Oct 2015 | 62 |
| NCT01888393Hepatic Impairment · Czech Republic, Slovakia | 1 | Completed | Vertex Pharmaceuticals | Nov 2013 | 23 |
| NCT01807949Cystic Fibrosis · United States, Australia, Austria and more | 3 | Completed | Vertex Pharmaceuticals | Apr 2014 | 563 |
| NCT01807923Cystic Fibrosis · United States, Australia, Canada and more | 3 | Completed | Vertex Pharmaceuticals | Apr 2014 | 559 |
| NCT01768663Cystic Fibrosis · United States | 1 | Completed | Vertex Pharmaceuticals | Sep 2013 | 80 |
| NCT01225211Cystic Fibrosis · United States, Australia, Belgium and more | 2 | Completed | Vertex Pharmaceuticals | Apr 2014 | 312 |
| NCT01216046Cystic Fibrosis · United States | 1 | Completed | Vertex Pharmaceuticals | May 2011 | 48 |
| NCT00966602Cystic Fibrosis · Netherlands | 1 | Completed | Vertex Pharmaceuticals | Dec 2009 | 24 |
| NCT00865904Cystic Fibrosis · United States, Belgium, Canada and more | 2 | Completed | Vertex Pharmaceuticals | Dec 2009 | 93 |
How it is read
Names in the registry
- “LUM/IVA”, 8 entries
- “Lumacaftor”, 5 entries
- “VX-809”, 4 entries
- “Lumacaftor Plus Ivacaftor Combination”, 3 entries
- “Lumacaftor 200 MG”, 1 entry
Conditions, from the studies’ own filings
- Cystic Fibrosis, 20 studies
- Cognitive Dysfunction, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.